GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.
GenSight Biologics has raised $1.1M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2026.
GenSight Biologics's investors include European Investment Bank, Bpifrance, Index Ventures, Invus, Perceptive Advisors.
GenSight Biologics is headquartered in Paris, France.
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.
GenSight Biologics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"GenSight Biologics — Funding & Investors." VCBacked, October 7, 2026, https://www.vcbacked.co/company/gensight-biologics. Accessed November 13, 2026.
VCBacked. (2026). GenSight Biologics — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/gensight-biologics
{{cite web |title=GenSight Biologics — Funding & Investors |url=https://www.vcbacked.co/company/gensight-biologics |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at GenSight Biologics? Request a listing update